For research use only. Not for therapeutic Use.
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease[1][2][3].
Dalazatide (ShK-186) (0-1000 pM) TFA blocks the Kv1.3 current in the Ova-specific GFP+ effector memory T (Tem) cells in a dose-dependent manner with a Kd of 65 ± 5 pM[3].
Dalazatide (0-100 nM; 3 days) TFA inhibits CCR7− T cell proliferation in a dose-dependent manner[3].
Dalazatide (100 nM; 30 min) TFA immobilizes effector memory T (Tem) cells at inflammatory sites by suppressing calcium signaling and thereby preventing β1 integrin activation[3].
Dalazatide (ShK-186) (100 μg/kg; s.c.; once) TFA inhibits delayed-type hypersensitivity and suppresses the in vivo motility and activation of Tem cells in rats[3].
| Catalog Number | I042350 |
| Molecular Formula | C184H296N57O55PS7.xC2HF3O2 |
| Purity | ≥95% |
| Reference | [1]. Olsen C, et al. Dalazatide (ShK-186), a first-in-class peptide inhibitor of Kv1. 3 potassium channels, demonstrates safety, tolerability and proof of concept of efficacy in patients with active plaque psoriasis. J. Invest. Dermatol., 2016, 136(8). [2]. Stevens A M, et al. Thu0285 Dalazatide, an Inhibitor of the KV1. 3 Channel on Activated Effector Memory T Cells, Has Immunotherapy Potential in Systemic Lupus Erythematosus. 2016. [3]. Matheu MP, et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 2008 Oct 17;29(4):602-14. |
